Brea C. Lipe, MD highlights key takeaways and patient outcomes from the PERSEUS phase three trial.
Brea C. Lipe, MD reviews the phase three randomized trial conducted by the European Myeloma Network compared induction therapy with Dara-VRd (daratumumab, lenalidomide, bortezomib, dexamethasone) versus VRd alone. The primary endpoint was progression-free survival. After a median follow-up of ~48 months, the 4-year PFS was significantly higher in the Dara-VRd arm at 84.7% vs 67.7% withVRD alone. The Dara-VRD arm also demonstrated improved depth of response, with higher rates of MRD negativity at multiple timepoints. This benefit with Dara-VRd was seen across most subpopulations, including high-risk patients. One exception was in older patients where there were too few patients and events to show a difference. Overall, the addition of daratumumab led to deeper responses and improved PFS. After transplantation, patients received 2 cycles of consolidation then went on lenalidomide maintenance, with the Dara- VRd arm receiving Dara-lenalidomide. Those who were MRD negative for 12+ months after 2 years could discontinue treatment. In summary, this robust trial provides evidence that adding daratumumab to standard induction/consolidation improves outcomes in eligible NDMM patients.
Summary was AI-generated and edited for clarity.